David Zaccardelli | executive |
Mark Hahn | executive |
Suji Jeong | analyst |
Christopher Martin | executive |
Andreas Argyrides | analyst |
Joon Lee | analyst |
Tara Rheault | executive |
Mitchell Kapoor | analyst |
Thomas Shrader | analyst |
Yasmeen Rahimi | analyst |
Welcome to Verona Pharma's conference call. [Operator Instructions] Earlier this morning, Verona Pharma issued a press release announcing top line results from its Phase III ENHANCE-2 trial, evaluating nebulized ensifentrine for the maintenance treatment of COPD. The company also issued a press release announcing its financial results for the 3 months ended June 30, 2022. Copies of both press releases can be found on the Investor Relations tab on the corporate website, www.veronapharma.com.
Before we begin, I'd like to remind you that during today's call, statements about the company's future expectations, plans and prospects are forward-looking statements.